%0 Journal Article
%T 围术期静脉输注利多卡因的研究进展<br>Research Progress on Perioperative Intravenous Infusion of Lidocaine
%A 张宝州
%A 刘逸凡
%A 郑晋伟
%J Advances in Clinical Medicine
%P 2349-2356
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.153870
%X 本研究基于既往综述文献并结合近几年发表的更多随机对照试验(RCTs)及系统评价&#65292;系统综述围术期静脉利多卡因的多维作用。研究发现&#65292;利多卡因静脉输注在肝脏、肿瘤及高危患者中表现出良好的安全性。其镇痛效应不仅涵盖乳腺癌、胸腔镜及腹部手术等术后急性疼痛&#65292;还能降低慢性疼痛发生率。机制研究表明&#65292;利多卡因通过抑制IL-6、重编程M2巨噬细胞及调控circRNA/miRNA轴&#65292;协同发挥抗炎抗肿瘤作用。<br>This study is based on the previous review literature combined with more published randomized controlled trials (RCTs) and systematic reviews in recent years to systematically review the multidimensional effects of perioperative intravenous lidocaine. Studies have found that intravenous infusion of lidocaine shows good safety in liver, tumor, and high-risk patients. Its analgesic effect not only covers acute postoperative pain such as breast cancer, thoracoscopy, and abdominal surgery, but also reduces the incidence of chronic pain. Mechanistic studies have shown that lidocaine synergistically exerts anti-inflammatory and anti-tumor effects by inhibiting IL-6, reprogramming M2 macrophages, and regulating the circRNA/miRNA axis.
%K 利多卡因&#65292
%K 多模式镇痛&#65292
%K 抗炎&#65292
%K 肿瘤微环境<br>Lidocaine
%K Multimodal Analgesia
%K Anti-Inflammatory
%K Tumor Microenvironment
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=110134